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Background: Norleucine and norvaline belong to a group of non-canonical amino acids which are synthesized as
byproducts in the branched chain amino acid metabolism of Escherichia coli. The earlier observed misincorporation
of these rare amino acids into recombinant proteins has attracted increasing attention due to the rising use of protein
based biopharmaceuticals in clinical application. Experimental data revealed pyruvate overflow inducing conditions,
which typically occur in oxygen limited zones of large-scale fermentations as a major reason leading to norvaline and
norleucine synthesis during E. coli cultivation. Previous approaches to suppress misincorporation of norleucine and
norvaline considered growth media supplementation with the relevant canonical isostructural compounds, but no
research was performed on the impact of the overflow metabolism related trace elements molybdenum, nickel and
selenium. These elements form essential parts of the formate hydrogen lyase (FHL) metalloprotein complex, which is a
key enzyme of anaerobic pyruvate metabolism in E. coli and could therefore represent a crucial connection to the
pyruvate accumulation associated biosynthesis of rare amino acids.
Results: In this study, the trace element associated response of recombinant antibody producing E. coli to oxygen
limitation at high glucose concentration with a special focus on non-canonical amino acids was analysed. During
fed-batch cultivation with provoked oxygen limitation and glucose excess norleucine and norvaline were only
accumulated in the absence of molybdenum, nickel and selenium. In contrast, the trace element supplemented
stress fermentation showed significantly reduced concentrations of these rare amino acids and the major signature
fermentation product formate, supporting the correlation between a functional formate hydrogen lyase complex
and low unspecific amino acid synthesis under oxygen limitation at high glucose concentration.
Conclusions: The formation of norleucine and norvaline by recombinant E. coli during cultivation with provoked oxygen
limitation and glucose excess can be reduced to levels at the detection limit by adding the trace elements molybdenum,
selenium and nickel to the fermentation medium. Even under the metabolic burden during induction phase the
physiologically available concentrations of non-canonical amino acids remained low. Since our results allow facile process
changes that can be easily implemented to avoid the undesirable accumulation of norleucine and norvaline, we consider
this study highly interesting for improved process development in E. coli based recombinant drug production and the
future development of possible mechanisms to reduce misincorporation events into protein based biopharmaceuticals.
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Beside the 20 canonical amino acids building up proteins
in nature, the rare amino acids norleucine and norvaline
can be formed by E. coli and some other gram-negative
species [1,2]. Both belonging to a group of branched-
chain amino acid analogues, norleucine was originally
observed in regulatory mutant strains of Serratia mar-
cescens [1], whereas norvaline was found to be part of an
antifungal peptide secreted by Bacillus subtilis [3].
More recently non-canonical amino acids have moved
into focus when their incorporation into recombinant
biopharmaceuticals during expression in E. coli was de-
tected. Prominent cases of therapeutically relevant pro-
teins with confirmed misincorporation are interleukin 2
and human brain derived neurotrophic factor showing
norleucine substitutions, as well as recombinant haemo-
globin with norvaline sequence variation [4-8].
According to the guidelines of regulatory health author-
ities like the US Food and Drug Administration (FDA) and
European Medicines Agency (EMA), all of this modified
variants of the final drug product need intensive analytical
characterization and are therefore highly undesirable in
biopharmaceutical production [9,10]. Furthermore, there is
only poor knowledge on the possible deleterious effects of
norleucine and norvaline containing protein therapeutics
in humans s, especially concerning an unwanted immuno-
genic response [11]. As a result of the high potential diver-
sity of human antibody reservoir, a by-product induced
autoimmune cross-reaction against endogenous proteins
could lead to severe health problems in patients [12,13].
And although the phenomenon of amino acid misincor-
poration is not regarded as an issue of relevant ICH Q6B
guidelines, it most likely becomes a particular regulatory
concern due to the increasing number of corresponding
reports. In addition to observed by-product formation in
E. coli, several cases of translational errors in antibody pro-
duction via mammalian Chinese hamster ovary (CHO)
cells were published quite recently, raising a potentially
fundamental problem throughout various expression plat-
forms [14-16]. The molecular event of norleucine and
norvaline incorporation into nascent peptide chain basic-
ally occurs via misaminoacylation of the cognate tRNA
[17,18]. Following the isostructural properties of norvaline
for leucine and norleucine for methionine, tRNAleu and
tRNAmet are mischarged by aminoacyl-tRNA synthetases
producing corresponding substitutions in the protein se-
quence [19,20].
The known biosynthesis of norleucine and norvaline in
E. coli is facilitated by the promiscuous enzymes of the
(iso)-leucine biosynthetic pathway [8,21,22]. Allowing the
utilization of diverse keto-acid substrates the enzymes
isopropylmalate-synthase (LeuA), isopropylmalate-isomerase
(LeuCD) and isopropylmalate-dehydrogenase (LeuB) of
the leuABCD-operon are supposed to catalyse a directchain elongation starting from the central carbon inter-
mediate pyruvate. The enzyme specificity of LeuA in E.
coli has not been under investigation yet, but data are
available for various substrates of the highly conserved
homolog in Salmonella typhimurium which possesses
condensation activity for pyruvate with acetyl-CoA [23].
The first extension product 2-ketobutyrate acts as a cru-
cial branched-chain amino acid precursor and is synthe-
sized from threonine under standard conditions. In the
subsequent reaction course 2-ketobutyrate is further
elongated towards the intermediates 2-ketovalerate and
2-ketocaproate which are finally transaminated to nor-
leucine and norvaline by the aminotransferases IlvE,
TyrA and AvtA.
Despite these facts, there exists just a limited under-
standing of the metabolic conditions leading to the syn-
thesis of non-canonical amino acids in E. coli. Current
physiological studies revealed strong evidence for the
connection of glucose overflow metabolism and pyruvate
accumulation to the occurrence of norvaline in wild-
type E. coli fermentations [22,24]. This is further sup-
ported by knock-out experiments showing that deletion
of the ilvA gene, which is responsible for 2-ketobutyrate
synthesis from threonine, results in significant higher
cellular norleucine and norvaline concentrations [20].
Since the effect of amino acid misincorporation is of
main interest in the area of industrial production of bio-
pharmaceuticals, the analysis of recombinant large-scale
overflow metabolism related to norleucine and norvaline
formation by E. coli is an essential prerequisite for the
development of any based process to avoid mistransla-
tion. Furthermore, E. coli represents the major bacterial
workhorse for the production of protein therapeutics,
currently providing 30% of all FDA and EMA approved
recombinant drugs [24].
Numerous studies describe the metabolic impact of
culture heterogeneities as a result of imperfect mixing in
large-scale bioprocesses [25,26], but surprisingly no
studies are accomplished on stress induced formation of
rare amino acids in recombinant E. coli cultivations re-
lated to anaerobic overflow metabolism. With this in
mind, our current research was inspired by a report
from Soini et al., which discusses the positive influence
of additional metal trace elements on anaerobic overflow
reactions in E. coli scale-down experiments [27]. The au-
thors showed that media supplementation with selen-
ium, nickel and molybdenum prevents toxic formate
accumulation under glucose excess and oxygen limited
conditions through a fully functional formate hydrogen
lyase enzyme (FHL) complex. However, the experiments
of Soini et al. were carried out using the E. coli wild-type
strain W3110 without including the additional metabolic
burden imposed on cell physiology by synthesizing a
heterologous protein. We therefore decided to employ
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body domain B10 in E. coli RV308 as a relevant example
for protein based biopharmaceuticals under current clin-
ical interest [28]. In three representative fed-batch culti-
vation set-ups the impact of molybdenum, nickel and
selenium on norleucine and norvaline accumulation
under oxygen limitation and glucose excess provoking
conditions was analysed and compared to a control fer-
mentation with sufficient oxygen supply. With this ap-
proach we want to further broaden the understanding of
norleucine and norvaline accumulation in recombinant
E. coli bioprocesses.
In this study we show the reduction of free norleucine
and norvaline formation under oxygen limited stress en-
vironment by medium supplementation with the FHL-
related trace elements. We therefore hypothesize that
potential channelling of the pyruvate knot towards for-
mate disproportion may feature a lower production of
non-canonical amino acids under large-scale production
conditions. Here we report for the first time a trace
element associated approach for the reduction of physio-
logically available unwanted amino acid species in recom-
binant E. coli fermentation processes.
Results and discussion
Dynamics of growth behaviour and glucose utilization
during oxygen downshift experiments
Since the metabolic response towards basic environmental
stress factors such as oscillating oxygen or substrate sup-
ply may result in reduced productivity [26,29-31] or caus-
ing severe modifications of the desired protein product, a
deeper understanding of fundamental mechanisms in rele-
vant biopharmaceutical processes is highly desirable.
In consequence the aim of this work focussed on the
so far disregarded influence of supplementary molyb-
denum, nickel and selenium on the formation of the
rare amino acids norleucine and norvaline during an
oxygen downshift in recombinant E. coli. We therefore
chose an E. coli RV308 production strain, expressing the
camelid antibody domain B10 as a model for possible
target molecules underlying current clinical interest. In
order to compare the obtained results to balanced culti-
vation conditions a glucose limited fed-batch reference
set-up with dissolved oxygen tension (DOT) above 20%
was performed (see Figure 1A). To ensure large-scale
stress conditions, oxygen limitation and glucose excess
during cultivation was provoked by a stepwise stirrer
down-shift and continuous linear feeding in the scale-
down fermentation set-ups (see Figure 1B,C). To allow
proper analysis of the E. coli cultivation samples, the
oxygen downshift was started at optical densities of
about OD600nm = 35, since lower cell densities showed
crucially varying results in amino acid analysis (unpub-
lished data). The growth of E. coli during referencefermentation indicated typical substrate consumption
and increasing biomass production up to a high cell
density of OD600nm = 72 at the end of induction phase.
In the experiments wherecells were exposed to an per-
manent oxygen downshift, cell growth during induction
phase arrested at lower levels around OD600nm = 30 as
expected. The oxygen limited cultivation with additional
Mo, Ni and Se showed slightly lower cell densities be-
tween OD600nm = 26 and 32 during the induction phase
compared to the cultivation without extra trace ele-
ments with an OD600nm between 30 and 36. This effect
is very likely a consequence of an increased carbon loss
through a higher carbon dioxide production related to
active FHL or an increased lactate accumulation which
was observed in similar experiments with permanent
oxygen downshift [27]. Concerning the lowered biomass
yield as a critical concern in industrial protein produc-
tion, the addition of Mo, Ni and Se could still be an op-
tion to test, since the authors also reported no negative
effects during experiments with oscillating oxygen and
glucose concentrations.
In addition, during the oxygen limited cultivation a
glucose accumulation of 4 g L-1 glucose without and up
to 10 g L-1 glucose with addition of extra trace elements
at the end of induction time was observed. These results
clearly correspond to earlier studies, showing a strong
inhibition on growth and glucose consumption when E.
coli is impaired with both, metabolic burden of recom-
binant expression and overflow metabolism [27,32,33].
Reduction of norleucine and norvaline accumulation by
medium supplementation with molybdenum, nickel and
selenium
The single most striking observation to emerge from the
data comparison was the significant reduction of norleu-
cine and norvaline accumulation by medium supplemen-
tation with molybdenum, nickel and selenium (Figure 2A
and B). In the oxygen limited cultivation set-up with add-
itional trace elements surprisingly low concentrations of
0.57 μM norleucine and 0.83 μM norvaline were detected
before induction and remained below that until the end of
the cultivation. In contrast, norleucine and norvaline ac-
cumulated up to 6.72 μM and 9.97 μM in the fermenta-
tion set-up without the addition of Mo, Ni and Se only 3 h
after feed start and further increased during the expres-
sion of B10. The time course analysis of the reference cul-
tivation revealed an increase of the non-canonical amino
acids upon induction of the recombinant expression with
isopropyl-β-D-thiogalactopyranosid (IPTG) (Figure 2).
Since the concentrations of norleucine and norvaline
showed the highest accumulation rates upon the induced
oxygen limitation and a substantial decrease before the
time point of induction, the relevance of oxygen limitation
















Figure 1 (See legend on next page.)
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Figure 1 E. coli RV308 growth dynamics during different cultivation modes used in this study. The graphs illustrate experimental data for
optical density (OD600nm), DOT and glucose concentration. (A) Glucose limited fed-batch cultivation on mineral salt medium with continuous feed
of glucose at constant feed rate of 10 g L-1 and indicated time point of induction (dashed line). (B) and (C) same as (A) but with a downshift of
DOT by a decrease of stirrer speed (arrow) and either without (B) or with (C) the addition of extra trace elements to the fermentation medium.
Stirrer downshift in (B) and (C) was performed 20 min before the start of glucose feeding to ensure glucose excess during cultivations. Samples
were collected from the beginning of continuous glucose feed.
Induction phase
RC
LC + Mo, Ni, Se




LC + Mo, Ni, Se
LC - Mo, Ni, Se 
B
Figure 2 Analysis of non-canonical amino acids from recombinant E. coli RV308 fed-batch cultivations. Concentration time course of
norleucine (A) and norvaline (B) during cultivation without (square) and with oxygen limiting conditions (circle and quadrate) from the time
point of feed start (zero hours). Dashed vertical lines indicate the process times for start of recombinant expression of B10.
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supported. By a simply addition of Mo, Ni, and Se to the
cultivation medium the accumulation of physiological
available unwanted non-canonical amino acids was signifi-
cantly reduced, which can become particularly relevant to
protein-based biopharmaceutical production processes
[11,16]. However, further investigations are essential to as-
sess the effect of reduced free norleucine and norvaline
concentrations on misincorporation rates in amino acid
sequence of the final protein product.
Differences in formate accumulation and recombinant
expression of antibody domain B10
The time course analysis of formate concentration dur-
ing the different E. coli cultivation set-ups indicated a re-
ducing effect to formate accumulation by additional Mo,
Ni and Se in the mineral salt medium in the oxygen lim-
ited culture. An overall 2-fold increased formate concen-
tration of up to 40 mM was measured in the oxygen
limited fermentation without additional trace elements
(Figure 3). In the large-scale mimicking cultivation per-
formed with Mo, Ni and Se supplemented medium, the
extracellular formate concentration was more than 50%
lower at the end of the induction phase compared to the
standard medium set-up. The obtained data of formate
accumulation were consistent with previous studies
showing the beneficial effect of additional Mo, Ni and Se
in the mineral salt cultivation medium of anaerobic E.
coli cultivations [27].
Besides this, the correlation between a higher cellular
capacity to disproportionate formate by cultivation in sup-Limited + Mo, Ni, Se
RC
LC - Mo,Ni, Se 
Figure 3 Formate accumulation profiles in the performed cultivation
graphs show data from cultivations without (square) and with oxygen limiting
and induction phase (vertical dashed line indicates time point of induction).plemented medium and a higher recombinant expression
level of B10 was apparent (Table 1). A final B10 protein
yield of 72.6 mg/L (without additional Mo, Ni, Se) and
137.5 mg/L (with additional Mo, Ni, Se) was measured for
the oxygen limited cultivations, whereas the reference fer-
mentation conditions ensuring sufficient oxygen supply,
showed an approximately 10-fold higher antibody yield of
2056.2 mg/L (Table 1). The latter observation of high re-
combinant expression is not surprising, since the central
carbon metabolism of the recombinant E. coli cells was
ideally balanced by optimal glucose feeding rate and oxy-
gen supply, keeping the metabolic burden as low as pos-
sible [32,33].
Connecting these findings with significantly lowered
norleucine and norvaline accumulation in the respective
fermentation scenarios, one might hypothesize that a
functional FHL enzyme complex can channel the pyru-
vate flux to disproportion of formate and avoiding accu-
mulation of unspecific precursors for non-canonical
amino acids [24,34].
Conclusions
In this study we could clearly show the trace element asso-
ciated reduction of norleucine and norvaline accumulation
during oxygen downshift experiments of biopharmaceut-
ical relevant recombinant E. coli fermentations. We identi-
fied the elements molybdenum, nickel and selenium as
key cultivation medium components reducing the forma-
tion of non-canonical amino acids under oxygen limitation
and glucose excess. Our findings might contribute to the
development of new strategies to avoid norleucine andInduction phase
types of E. coli RV308 with recombinant expression of B10. The
conditions (circle and quadrate) from the time of feed start (zero hours)
Table 1 Analysis of recombinant protein yield, OD600nm at
end of cultivation and stirrer rate during expression
phase of E. coli RV308 B10




Reference 1000 73 2056.2




The protein yield data are given as the mean between three measurements.
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further improve recombinant pharmaceutical production
in accordance to current international guidelines.
Methods
Strain
The strain used in this study was Escherichia coli K-12
RV308 ATCC 31608x [su-, ΔlacX74, gal IS II::OP308,
strA] transformed with plasmid p41B10aP [28]. Stock
solution of the strain was stored in 25% [v/v] glycerol so-
lution supplemented with mineral salt medium.
Precultures
All precultures were cultivated at 30°C on a rotary
shaker set to 200 rpm. The initial precultures were per-
formed in 10 mL of LB medium supplemented with
ampicillin (100 μg mL-1) in 100 mL Erlenmeyer flasks
for 8–12 hours inoculated with E. coli stock solution.
The second precultures for inoculation of bioreactors
were performed in 1000 mL Erlenmeyer flasks filled with
100 mL of the respective bioreactor mineral salt medium
supplemented with 10 g L-1 glucose.
Bioreactor cultivations
The fed-batch cultivations were performed in a Sixfors
bioreactor (Infors, Switzerland) equipped with DCU-3
controlling unit and MFCS-monitoring system (Sartorius,
Germany) starting with 0.4 L working volume. Main
cultures were inoculated with liquid precultures to a
starting OD600 of 0.15. The defined mineral salt cultiva-
tion medium was prepared in distilled water containing
per L: 8.6 g Na2HPO4 × 12 H2O, 0.5 g NaCl, 3 g KH2PO4,
1 g NH4Cl, 10 mL Fe-citrate (0.023 M), 0.1 mL EDTA
(0.2 M), 0.1 mL CoCl2 × 6 H2O (0.1 M), 0.1 mL MnCl2 ×
4 H2O (0.75 M), 0.1 mL CuCl2 × 4 H2O (0.1 M), 0.1 mL
H3BO3 (0.5 M), 2 mL Zn(CH3COO)2 × 2 H2O (0.018 M),
5 mL MgSO4 (1 M), 0.1 g thiamine hydrochlorid and
1 mL antifoam agent. In order to examine the effect of
medium supplementation with molybdenum, nickel andselenium, these additional trace elements were initially
added to the indicated cultivation to a final concentration
of: 0.24 mg L-1 Na2Mo × 5 H2O, 1.45 mg L
-1 Ni(NO3)2 ×
6 H2O and 0.17 mg L
-1 Na2SeO3 × 5 H2O [27]. The culti-
vation temperature was 30°C and pH was kept at 6.8 by
controlled feeding of 10% ammoniumhydroxid. The fer-
mentation media contained an initial glucose concentra-
tion of 15 g L-1, the feed solution contained 500 g L-1
glucose. Reference cultivation was performed in glucose
limited fed-batch mode with controlled DOT set point at
30%. The metabolic shift in scale-down fermentations was
initialized at the end of exponential growth phase by low-
ering the stirrer rate from 1000 rpm to 500 rpm. The glu-
cose feeding was started 20 min after stirrer downshift
with a constant rate of 10 g L-1 h-1 to ensure glucose ex-
cess during the whole cultivation. For protein expression,
cultures were induced with 1 mM IPTG.Analysis of cell growth
Cell growth was monitored by measurement of absorb-
ance (OD600nm) with a Spekol spectrophotometer (Carl
Zeiss, Germany).Amino acid analysis
Fermentation samples for amino acid analysis of clarified
crude broth lysates were immediately quenched in −40°C
cold 60% methanol and subsequently shock-frozen in li-
quid nitrogen. Samples were stored at −80°C until ana-
lysis. The sample preparation for HPLC included dilution
of samples to the same cell density with 0.9% NaCl, a sub-
sequent sonification step for 10 min on ice, removal of cell
debris and deproteinization by centrifugation for 10 min
(4°C, 16.000 × g) and ultracentrifugation of supernatant
using Amicon Ultra 3 kDa cut-filter devices (Millipore.
The HPLC analysis was performed with a JASCO X-LC
HPLC system (JASCO Corporation, Japan), containing
autosampler unit, intelligent column thermostat, fluor-
escence detector and a Nucleodur C18 Gravity column
(Macherey-Nagel, Germany). Pre-column derivatization
of 30 μL sample solution and 30 μL OPA reagent
(Sigma-Aldrich, Germany) was carried out for 30 s in
autosampler unit, followed by injection of 1 μL onto col-
umn. HPLC analysis was further performed as described
earlier [34].Analysis of glucose and formate
Glucose and formate concentrations were analysed from
medium samples, which were immediately centrifuged
for 5 min (4°C, 16.000 × g), filtered (0.2 μm) and shock-
frozen in liquid nitrogen. Glucose was analysed with ECA
2000 unit (YSI Life Sciences, USA). Formate was analysed
with Formiat Assay Kit (Bio Vision, Germany).
Biermann et al. Microbial Cell Factories 2013, 12:116 Page 8 of 9
http://www.microbialcellfactories.com/content/12/1/116Quantification of B10aP
Determination of correctly folded B10aP was performed
by enzyme activity assay and calculated by means of a
standard curve. Colorimetric detection was performed
with the PNPP (p-nitrophenyl phosphate, disodium salt)
substrate (Pierce) for alkaline phosphatase. Samples of
1 mL were taken before and every hour during induction
phase, followed by immediate shock-freezing in liquid
nitrogen, sonification for 10 min on ice and removal of
cell debris by centrifugation.
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